Microwave Ablation in Combination with Chemotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer
Microwave Ablation in Combination with Chemotherapy for the Treatment of Advanced Non-Small Cell Lung Cancer
复制标题
DOI：
10.1007/s00270-014-0895-0
复制
发表时间：
2015-02-01
影响因子：
2.9
通讯作者：
Han, Xiaoying
中科院分区：
文献类型：
--
作者：
Wei, Zhigang;Ye, Xin;Han, Xiaoying
为了验证微波消融（MWA）作为局部对照治疗是否能改善晚期非小细胞肺癌（NSCLC）的预后，39例经组织学证实的晚期NSCLC患者入选，其中至少有一个可测量部位不是消融部位。原发性肿瘤接受MWA，然后接受基于铂的双联化疗。采用改良的实体瘤疗效评价标准（mRECIST）和RECIST评价治疗疗效。使用美国国家癌症研究所通用毒性标准（3.0版）评估并发症。MWA应用于39例患者的39个肿瘤。原发肿瘤的平均直径和中位直径分别为3.84 cm和3.30 cm，范围为1.00-9.00 cm。33例（84.6%）患者获得部分缓解。MWA疗效与临床病理特征无相关性。对于化疗，11例患者（28.2%）达到部分缓解，18例（46.2%）显示疾病稳定，10例（25.6%）疾病进展。总体客观缓解率和疾病控制率分别为28.2%和74.4%。中位无进展生存期为8.7个月（95% CI 5.5-11.9）。中位生存期为21.3个月（95%CI 17.0-25.4）. 22例（56.4%）患者出现并发症，3例（7.9%）患者出现3级不良事件，MWA联合化疗可使晚期NSCLC患者获益。与MWA相关的并发症常见但可耐受。
To verify whether microwave ablation (MWA) used as a local control treatment had an improved outcome regarding advanced non-small cell lung cancer (NSCLC) when combined with chemotherapy.Thirty-nine patients with histologically verified advanced NSCLC and at least one measurable site other than the ablative sites were enrolled. Primary tumors underwent MWA followed by platinum-based doublet chemotherapy. Modified response evaluation criteria in solid tumors (mRECIST) and RECIST were used to evaluate therapeutic response. Complications were assessed using the National Cancer Institute Common Toxicity Criteria (version 3.0).MWA was administered to 39 tumors in 39 patients. The mean and median diameters of the primary tumor were 3.84 cm and 3.30 cm, respectively, with a range of 1.00-9.00 cm. Thirty-three (84.6 %) patients achieved a partial response. No correlation was found between MWA efficacy and clinicopathologic characteristics. For chemotherapy, 11 patients (28.2 %) achieved a partial response, 18 (46.2 %) showed stable disease, and 10 (25.6 %) had progressive disease. The overall objective response rate and disease control rate were 28.2 and 74.4 %, respectively. The median progression-free survival time was 8.7 months (95 % CI 5.5-11.9). The median overall survival time was 21.3 months (95 % CI 17.0-25.4). Complications were observed in 22 (56.4 %) patients, and grade 3 adverse events were observed in 3 (7.9 %) patients.Patients with advanced NSCLC could benefit from MWA in combination with chemotherapy. Complications associated with MWA were common but tolerable.